1,579 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B Buy
Article Searches
Merck's Keytruda Gets FDA Approval for Rare Skin Cancer http://www.zacks.com/stock/news/343978/mercks-keytruda-gets-fda-approval-for-rare-skin-cancer?cid=CS-ZC-FT-343978 Dec 20, 2018 - Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Eli Lilly CEO on winning in migraine treatments: 'It's a horse race between three great companies' https://www.cnbc.com/2018/12/19/eli-lilly-on-migraine-treatment-race-between-lilly-amgen-and-teva.html Dec 19, 2018 - Jim Cramer and Eli Lilly CEO Dave Ricks speak about competition in the migraine treatment space and how Eli Lilly plans to win out.
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY http://www.zacks.com/stock/news/343701/biotech-stock-roundup-pipeline-updates-from-vrtx-amgn-adro-teams-up-with-lly?cid=CS-ZC-FT-343701 Dec 19, 2018 - A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma http://www.zacks.com/stock/news/343512/mercks-keytruda-gets-eu-nod-as-adjuvant-therapy-for-melanoma?cid=CS-ZC-FT-343512 Dec 18, 2018 - Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
Teva Reports Positive Top-Line Data for Migraine Candidate http://www.zacks.com/stock/news/343485/teva-reports-positive-top-line-data-for-migraine-candidate?cid=CS-ZC-FT-343485 Dec 18, 2018 - Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019 http://www.zacks.com/stock/news/342956/5-drug-biotech-stocks-with-promise-to-sustain-bull-run-in-2019?cid=CS-ZC-FT-342956 Dec 14, 2018 - The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Why Biotech Asset Managers Can (Should?) Make Money In Any Markets https://seekingalpha.com/article/4228125-biotech-asset-managers-can-make-money-markets?source=feed_sector_healthcare Dec 13, 2018 - IBB is iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index.In the last three years, IBB has remained flat and significantly underperformed the S&P 500.For retail investors, we think i
Has Celgene Entered Bargain Territory? http://www.gurufocus.com/news/783818/has-celgene-entered-bargain-territory Dec 11, 2018 - Has Celgene Entered Bargain Territory?, Stocks: CELG,GILD,BIIB,AMGN, release date:Dec 11, 2018
Entera Bio up 42% premarket on Amgen collaboration https://seekingalpha.com/news/3415951-entera-bio-42-percent-premarket-amgen-collaboration?source=feed_news_all Dec 11, 2018 - Ultra-thinly traded nano cap Entera Bio (ENTX) is up 42% premarket on triple normal volume, albeit on turnover of only 8,300 shares, in response to its research collaboration and license agreement wit
Challenges For Gilead's 2 New CEOs https://seekingalpha.com/article/4227475-challenges-gileads-2-new-ceos?source=feed_tag_editors_picks Dec 10, 2018 - GILD has announced an interim CEO, a GILD veteran, followed by a heavy hitter, the head of Roche's Pharma division, Daniel O'Day.I think there are aspects to GILD's pipeline strategy and communication

Pages: 123456789...158

<<<Page 4>